Think CMC is just about process development and documentation? Think again.
In biotech, Chemistry, Manufacturing, and Controls (CMC) is often mistaken for a static checklist—define your process, lock your documents, and move on. In reality, CMC is a living, evolving strategy that touches every part of drug development, from early research to commercial launch. It defines how you scale, how you pass regulatory inspections, and ultimately, whether your product can get to patients safely and on time.
The founders who thrive don’t just “do” CMC; they use CMC as a strategic lever to anticipate risk, build resilience, and align technical execution with business reality. Here are the high-stakes challenges that separate successful biotech startups from those that stall or fail.
1. Regulatory Navigation: Understanding the Moving Target
In theory, “phase-appropriate” data collection should be straightforward—you provide enough information for the clinical stage you’re in and build detail over time. In practice, regulatory navigation is one of the most complex and underestimated parts of CMC strategy. FDA and EMA guidance documents can be hundreds of pages long, full of cross-references and conditional requirements that hinge on subtle product-specific factors. What counts as “sufficient” for a Phase I IND can look completely different depending on whether you’re working on a small molecule, monoclonal antibody, or cell therapy.
Regulators expect not just compliance, but a clear plan for how your process will mature as you move from early safety trials to pivotal efficacy studies. If you invest too heavily in characterization at Phase I, you risk burning precious capital on work that may have to be redone after process changes. If you under-invest, you may find your Phase III submission rejected for inadequate validation—forcing you to rebuild your manufacturing strategy from scratch.
- Early-stage (Phase I): Regulators expect a process that is safe, reproducible, and suitable for human use, but not fully locked. Over-investing in full process characterization too soon can burn resources.
- Late-stage (Phase III): The same agencies will expect robust process validation, thorough characterization, and commercial-readiness. Missing these requirements can lead to complete redevelopment of manufacturing processes, delaying timelines by years.
Strategic approach: Build your CMC program in phases, with a clear roadmap for how analytical methods, manufacturing processes, and documentation will mature alongside clinical development. Engage regulators early and often to confirm expectations before committing resources.
2. Supply Chain Resilience: Planning for the Unplanned
If the last few years proved anything, it’s that biotech supply chains are fragile by default. The COVID-19 pandemic, geopolitical tensions, and even regional natural disasters have demonstrated that single-source suppliers can become points of failure overnight. This risk is amplified in biopharma manufacturing, where critical raw materials—like GMP-grade media components, viral vector plasmids, or sterile filters—often have long lead times and few qualified producers.
Many startups focus almost entirely on lab and process development in early phases, assuming supply continuity will be addressed later. That’s a dangerous assumption. By the time you’re scaling up for Phase II or III, any disruption in a critical input can stall manufacturing, jeopardize trial timelines, and trigger a cascade of regulatory amendments. For certain niche materials, global capacity can be so tight that losing a supplier means a six- to twelve-month delay.
- Risks: Single points of failure, regulatory requirements for dual sourcing, geopolitical instability.
- Impact: Delayed batch release, missed clinical milestones, and spiraling costs from emergency sourcing.
Strategic approach: Develop multiple qualified suppliers early, even if it means higher upfront costs. Build supplier audits and performance tracking into your quality system. Consider local or regional sourcing where possible, and keep safety stocks of critical raw materials.
3. Innovation vs. Cost Balance: Managing the Technology Trade-Off
Biotech founders are often drawn to state-of-the-art manufacturing platforms—continuous bioprocessing, advanced automation, novel analytical tools—because of their potential to increase efficiency or improve product quality. While these technologies can provide real competitive advantages, they also carry risks: limited operational track record, steep learning curves, and higher upfront investment. On the other side of the spectrum, sticking to legacy methods can reduce near-term risk but create scale and cost bottlenecks that slow long-term growth.
This balance is especially delicate for startups with finite funding windows. Investors expect technical innovation but also scrutinize capital allocation. Choosing a bleeding-edge manufacturing approach without a fallback plan can lock you into a path that’s hard to reverse if performance or regulatory acceptance falls short. Conversely, delaying technology adoption for too long can leave you unprepared for commercial-scale demands or unable to differentiate your product in a crowded market.
- Risks: Over-investing in novel platforms that are unproven at scale. Under-investing in enabling technology that later becomes a bottleneck.
- Impact: Burn rate acceleration, manufacturing delays, and loss of competitive advantage if technology transitions midstream.
Strategic approach: Apply a risk-based approach—pilot new technologies where they offer meaningful cost or time savings, but keep backup processes ready. Leverage CDMO infrastructure to de-risk scale-up before committing to expensive internal builds.
4. The Partnership Paradox: Outsourcing Without Losing Control
Few biotech startups can build complete manufacturing and quality infrastructures in-house during early development. Partnering with CDMOs, CROs, and specialized consultants is often essential for accessing expertise, facilities, and speed. However, outsourcing also creates dependency. When knowledge, processes, and data are controlled externally, your company risks losing critical know-how that will be vital for scale-up and commercialization.
Additionally, staff turnover at service providers can mean your “core” process experts aren’t the same people six months later. If that expertise isn’t documented and transferred internally, you may find yourself unable to troubleshoot issues or defend regulatory filings. Outsourced partners may also prioritize other clients, leading to delays if you lack contractual protections or strong governance structures.
- Risks: Knowledge gaps if a partner changes staff or priorities. Dependence on external systems that don’t integrate with your own.
- Impact: Reduced agility, slower problem-solving, and inability to pivot without starting from scratch.
Strategic approach: Treat partnerships as strategic alliances, not transactional relationships. Build joint governance structures, retain internal CMC leadership, and require full documentation handover. Ensure all key decisions, methods, and data are captured in your own quality systems.
5. Product-Specific Strategy: Rejecting the Cookie-Cutter Approach
Biotech product modalities vary widely, and each brings unique CMC considerations. A monoclonal antibody may leverage platform processes for cell line development and purification, but still require bespoke analytical methods for potency or impurity profiling. A gene therapy vector might be produced in adherent cells for early work, but scaling to suspension systems can change product quality attributes. A cell therapy may demand specialized closed-system manufacturing to avoid contamination risk.
Despite these differences, many companies adopt generic CMC strategies because they seem faster or cheaper to implement. This short-term mindset often backfires when product-specific needs emerge mid-development, requiring major process changes that trigger comparability studies, regulatory amendments, and new stability programs.
- Biologics example: Your monoclonal antibody may require unique cell culture conditions or novel purification steps not covered by generic platform processes.
- Cell & gene therapy example: Your viral vector process may have scale limitations, cold-chain dependencies, and analytical method gaps that require bespoke solutions.
Strategic approach: Build CMC around the specific biological and regulatory profile of your product. Conduct gap analyses early, and design manufacturing, QC, and stability programs tailored to your therapeutic’s unique characteristics.
6. Cross-Functional Orchestration: Making CMC a Company-Wide Language
CMC doesn’t operate in isolation—it connects directly with clinical, regulatory, quality, and commercial functions. A clinical team changing trial endpoints may require the development of new assays. A regulatory shift might force updates to quality systems. A manufacturing deviation can cascade into delays in clinical supply, which can impact trial enrollment and investor confidence.
In many startups, these interdependencies are poorly managed because teams work in silos, each focused on immediate deliverables. Without active cross-functional communication, changes in one area can create surprises and bottlenecks elsewhere. This lack of orchestration is especially damaging in lean organizations where staff wear multiple hats and timelines are compressed.
- Risks: Silos between CMC, clinical, regulatory, and quality teams delay decisions and create rework.
- Impact: Missed milestones, duplicated effort, and misaligned priorities.
Strategic approach: Create integrated project teams that include representatives from all functional areas. Use shared systems for document control, risk registers, and timelines. Make CMC updates a standing agenda item in cross-functional governance meetings.
Conclusion: CMC as a Strategic Asset, Not a Checklist
The difference between winners and losers in biotech often comes down to how they view CMC. Losing startups treat it as a box to tick—sometimes late in the game, when it’s too late to course-correct. Winning startups treat CMC as an evolving strategic framework from day one, embedding it into every technical and business decision.
✔️ They build roadmaps that anticipate regulatory, supply, and scale-up challenges.
✔️ They invest in systems that scale with the company, not just the current phase.
✔️ They create processes designed to adapt as the product, the market, and the regulations change.
In a sector where every month counts, this mindset transforms CMC from a compliance obligation into a competitive advantage. It allows startups to move faster, manage risk proactively, and protect both timelines and capital.
If you’re a biotech founder or CMC leader, ask yourself: is your CMC strategy built to survive the unexpected? If the answer isn’t an immediate yes, now is the time to rethink your approach—before the next disruption, guidance change, or supply chain crisis forces your hand.
Are you looking for a CDMO? Learn more about our favorite here–> Aquaterra Biotech
